PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Apr 03      Thu - Apr 04      Fri - Apr 05      Sat - Apr 06   

SATURDAY, APRIL 6

6:30 - 1:00 PM
EVENT/OTHER
REGISTRATION
Chicago Promenade

7:00 - 8:00 AM
SATELLITE SYMPOSIUM
FINDING THE TRUSTED FACTOR: 10 YEARS OF FIX EXPERIENCE ACROSS AGES AND SETTINGS (SPONSORED BY SANOFI)
Chicago Ballroom VI

This presentation highlights a decade of experience (since FDA approval) with a Factor IX therapy, exploring its impact across various age groups and settings. You will hear from clinical experts and a patient as they share insights and experience with an EHL FIX therapy that has been trusted for 10 years.



PARADIGM SHIFTS IN HEMOPHILIA PROPHYLAXIS: PUTTING EVIDENCE INTO PRACTICE (SPONSORED BY CLINICAL CARE OPTIONS, LLC)
Chicago Ballroom IX-X

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Joint Accreditation Statement In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education CCO designates this live activity for a maximum of 2. 0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


8:15 - 9:45 AM
HEMOSTASIS / BASIC SCIENCE
BLEEDING IN HYPERMOBILITY/EHLERS DANLOS
Sheraton Ballroom I-II


8:15

ASSESSMENT AND MANAGEMENT OF BLEEDING IN PEDIATRIC PATIENTS WITH HYPERMOBILITY SYNDROME
Nicole Kendel.


8:45

PREGNANCY COMPLICATIONS AND OUTCOMES IN EHLERS DANLOS SYNDROME
Ashley Benson.


9:15

CONTRIBUTION OF PLATELET DYSFUNCTION TO BLEEDING IN EHLERS DANLOS SYNDROME
Mariia Kumskova.

8:15 - 9:45 AM
LABORATORY
QUALITY IMPROVEMENT EFFORTS IN LABORATORY HEMOSTASIS/THROMBOSIS TESTING
Chicago Ballroom VII


8:15

PREANALYTIC VARIABLES -- (UPDATES INCLUDING CLSI)
Annie Winkle.


8:45

FACTOR XIII TESTING- WHAT IS AVAILABLE? WHAT ARE BEST PRACTICES FOR TESTING? EFFECT OF CONCENTRATES ON LAB TESTS? ANTIGEN VERSUS ACTIVITY TESTING? ANY REMAINING ROLE FOR CLOT SOLUBILITY?
Natalie Mathews.


9:15

PLATELET AGGREGATION TESTING IN THROMBOCYTOPENIC PATIENTS
Cathy Hayward.

8:15 - 9:45 AM
THROMBOSIS
YOUNG, WILD AND VTE - TREATMENT CONSIDERATIONS FOR ADOLESCENTS AND YOUNG ADULTS
Sheraton Ballroom IV-V


8:15

PULMONARY EMBOLUS IN ADOLESCENTS: TREATMENT CHALLENGES AND OPPORTUNITIES
Julie Jaffray.


8:45

CONTINUING "THE PILL" OR NOT?: VTE TREATMENT AND EXOGENOUS HORMONES
Marie-Claude Pelland Marcotte.


9:15

THE CHANGING LANDSCAPE OF ANTICOAGULATION TREATMENT IN CHILDREN
Laura Avila.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A2. PLATELET ACTIVATION AND BIOCHEMISTRY




INCIDENCE OF ITP BEFORE AND AFTER COVID-19: A NATIONWIDE INPATIENT SAMPLE STUDY
Khaldun M. Obeidat, Ekrem Turk , Maryam Zia . John H Stroger health system, Chicago, IL, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION




EVALUATING DIAGNOSTIC ALGORITHMS FOR HEPARIN-INDUCED THROMBOCYTOPENIA USING TWO COMBINED RAPID AUTOMATED ASSAYS
Anna-Lise Bissola1, 2, Yi Zhang1, 3, Madison Cranstone2, 4, Donald Arnold1, 2, Ishac Nazy1, 2. 11. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada. 2Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 3. Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada. 32. Michael G. DeGroote Centre for Transfusion Research, McMaster University, 4. Department of Statistics and Actuarial Science, University of Waterloo, Hamilton, ON, Canada. 41. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada. 51. Faculty of Medicine, Michael DeGroote School of Medicine, McMaster University, 2. Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS




INSIGHT INTO ATHN 16: TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS TO EVALUATE THE SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW
Tammuella Chrisentery-Singleton1, SUCHITRA ACHARYA2, SANJAY AHUJA3, LAUREN AMOS4, MEERA CHITLUR5, MIGUEL ESCOBAR6, ASHLEY EASON7, SHVETA GUPTA8, PHILLIP KURIAKOSE9, SHARON PENNINGTON10, RAJIV PRUTHI11, MICHAEL RECHT12, SPENCER SULLIVAN13, DORIS QUON14, ALLISON WHEELER15, MARK REDING16. 1American Thrombosis and Hemostasis Network, Rochester, NY, USA. 2Northwell Health Hemostasis and Thrombosis Center, New Hyde Park, NY, USA. 3University Hospitals Health System Cleveland, Cleveland, OH, USA. 4Childrena, Kansas City, MO, USA. 5Central Michigan University/Childrena, Detroit, MI, USA. 6University of Texas Health Science Center, Houston, TX, USA. 7Willett Children's Hemophilia Treatment Center at Memorial Health, Savannah, GA, USA. 8Arnold Palmer Hospital for Children, Orlando, FL, USA. 9Henry Ford Health System, Detroit, MI, USA. 10Louisiana Center for Advanced Medicine, Slidell, LA, USA. 11Mayo Clinic, Rochester, MN, USA. 12National Blood Disorders Foundation, New York, NY, USA. 13Mississippi Center for Advanced Medicine, Madison, MS, USA. 14Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. 15Vanderbilt University Medical Center, Nashville, TN, USA. 16University of Minnesota Medical Center, Minneapolis, MN, USA




IMPACT OF MRNA COVID-19 VACCINATION ON D-DIMER LEVELS AND ANTI-PF4 SEROCONVERSION IN HEALTHY ADULTS: A SYSTEMATIC REVIEW
Evan Y Maroun M. S. , Megan Centrella, Grace Hansen, Trevor Forsberg, Tariq Rahaman M. L. I. S. , Hoang Nguyen M. D. Ph. D. . Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, USA




UTILITY OF THROMBOELASTOGRAPHY VERSUS ROUTINE COAGULATION TESTS: CARDIAC BYPASS SURGERY.
ISABEL RODRIGUEZ MARTIN. Hospital Universitario Virgen del Rocio, SEVILLA, Spain


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS




CLINICAL OUTCOMES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA WITH AND WITHOUT PROPHYLAXIS THERAPY: A MULTINATIONAL CHART REVIEW STUDY
Paul Coppo1, Marie Scully2, Johanna A Kremer Hovinga3, Maria Jose Aragon4, Parth Patwari5, Linda T Wang5, BjAprn MellgAyrd5, Ragy Saad5. 1APHP. 6a, Paris, France. 2University College London Hospitals NHS Foundation Trust, London, United Kingdom. 3Department of Hematology and Central Hematology Laboratory, Bern University Hospital, Bern, Switzerland. 4HCD Economics, Knutsford, United Kingdom. 5Takeda Development Center Americas, Inc, Cambridge, MA, USA




TEMPORAL TRENDS AND PREDICTORS OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
Michael Imeh1, Ani Gvajaia1, Chukwunonye Amaeshi2, Fidelis Uwumiro3. 1Lincoln Medical and Mental Health Centre, Bronx, NY, USA. 2Montefiore Medical Centre, Bronx, NY, USA. 3University of Benin Teaching Hospital, Benin, Nigeria




DEEP PHENOTYPING REVEALS A HIGH PREVALENCE OF DISTRESSING BLEEDING SYMPTOMS IN PATIENTS WITH HYPERMOBILE EHLERS DANLOS SYNDROME (HEDS) SPECTRUM DISEASE .
Rohith Jesudas1, Sarah Mathena 2, Kenneth Zhang3, Christina Laukaitis3, 4, Jennifer Andrews2. 1St. Jude Childrena, Memphis, TN, USA. 2University of Arizona, Tucson, AZ, USA. 3Carle Illinois College of Medicine, Urbana, IL, USA. 4Carle Foundation Hospital, Urbana, IL, USA




INDIRECT COMPARISON OF PROPHYLAXIS EFFICACY BETWEEN SIMOCTOCOG ALFA AND EFANESOCTOCOG ALFA IN SEVERE HEMOPHILIA A AND THEIR COST IN THE UNITED STATES
Craig M. Kessler1, Fernando F. Corrales-Medina2. 1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, DC, USA. 2University of Miami-Miller School of Medicine, and University of Miami-Hemophilia Treatment Center, Miami, FL, USA




RISK OF THROMBOSIS IN SGLT2 INHIBITOR-ASSOCIATED ERYTHROCYTOSIS: A MULTI-CENTER PROPENSITY-MATCHED ANALYSIS
Meric Mericliler1, 2. 1Division of Hematology and Medical Oncology, Virginia Commonwealth University Health, Richmond, VA, USA. 2Massey Cancer Center, Richmond, VA, USA




HOSPITALIZATION OUTCOMES FROM VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE DATA FROM 2016 TO 2019
Youjin oh, Alejandro Vallejo, Alexandra Sueldo, Lina james, Angelo Caputi Zuniga, Ayobami Olafimihan, Ekrem Turk. John H. Stroger Jr Hospital, Chicago, IL, USA




ACCURATE MEASUREMENT OF FACTOR VIII ACTIVITY AND INHIBITORS IN THE PRESENCE OF MIM8
William Pickering1, Karin Nana Weldingh2, Mary Robinson1, Caroline Cogswell1, Wan Hui Ong Clausen2, Mirella Ezban2, Vlady Ostrow3. 1Labcorp Colorado Coagulation, Englewood, CO, USA. 2Novo Nordisk A/S, SAcborg, Denmark. 3Novo Nordisk Inc, Plainsboro, NJ, USA




FIRST REAL-WORLD EXPERIENCE ADMINISTERING ETRANACOGENE DEZAPARVOVEC GENE THERAPY FOR PEOPLE WITH HEMOPHILIA B
Matthew Ryan1, Andrea B. Miller1, Patrick O'Hearn1, Vidhi Desai2, Nathan Visweshwar3. 1Hemophilia Outreach Center, Green Bay, WI, USA. 2CSL Behring, King of Prussia, PA, USA. 3University of South Florida, Tampa, FL, USA


A7. PATHOPHYSIOLOGY OF THROMBOSIS




THROMBOSIS RATES AND USE OF THROMBOPROPHYLAXIS AFTER DISCHARGE FROM GYNECOLOGIC CANCER-RELATED SURGERY
Leticia Campoverde, Alyssa Mercadel, Dan Morgenster, Asaad Trabolsi, Thomas Plate IV, Rachel Kronenfeld, Wei Zhao, Matthew Schlumbrecht , Gerald Soff. University of Miami, Miami, FL, USA


A8. ANTITHROMBOTIC THERAPY




INCIDENCE OF GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIOVASCULAR PATIENTS TAKING ANTITHROMBOTIC MEDICATIONS WITH PROTON PUMP INHIBITORS
Mark Edwards1, Xiaowen Kong1, Jacob Kurlander1, Scott Kaatz2, James B Froehlich1, Twylla Tassava3, Christopher Giuliano4, Geoffrey D Barnes1. 1University of Michigan-Michigan Medicine, Ann Arbor, MI, USA. 2Henry Ford Health- Division of Hospital Medicine, Detroit, MI, USA. 3Trinity Health-Ann Arbor, Ann Arbor, MI, USA. 4Ascension- St. John Hospital, Detroit, MI, USA




ACCURACY OF A WARFARIN CLINICAL DOSING ALGORITHM ENRICHED WITH GENETIC INFORMATION COMPARED TO THE USE OF CLINICAL ALGORITHM
Amr Fahmi1, Ahmed El Bardissy1, Mohamed Saad1, Mohamed Nabil1, Loulia Bader2, Mohamed Kassem1, Ahmed Mahfouz1, Hazem Elewa2. 1Hamad Medical Corporation, Doha, Qatar. 2College of Pharmacy, QU Health, Qatar University, Doha, Qatar


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)




SAFETY AND COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULATION THERAPY IN ADULT PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION
Amanda Arenella1, Michael Calloway1, Joshua Oh2. 1Department of Health Economics and Outcomes Research, Grifols SSNA, Research Triangle Park, NC, USA. 2University of North Carolina at Charlotte, College of Health and Human Services, Department of Public Health Sciences, Charlotte, NC, USA




WHAT IS THE ROLE OF FAMILY HISTORY IN THE MANAGEMENT OF VTE?
Ayan Ramanathan1, Ishan Dhaneshwar1, Joseph Caprini3, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Krish Punyarthi1, Richa Mahajan1. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA. 3Northshore University Health System, Evanston, IL, USA

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - BLEEDING: OUTCOMES AND PREDICTORS
Sheraton Ballroom I-II


10:30

SOCIAL VULNERABILITY AND HEMOPHILIA CARE AND OUTCOMES
Pooja Vijayvargiya1, Binh Le2, Christine L. Kempton1, 3, Vanessa R. Byams2, Brandi Dupervil2, Meredith Oakley2, Stacey A. Fedewa1, 3. 1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. 2Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 3Hemophilia of Georgia Center for Bleeding a Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA


10:45

HEAVY MENSTRUAL BLEEDING MAY BE DRIVEN BY LOCALIZED ENDOMETRIAL COAGULOPATHY
Bethany T Samuelson Bannow1, Leslie Myatt2, Alison Edelman2. 1Hemostasis a Thrombosis Center at Oregon Health a Science University, Portland, OR, USA. 2Department of Obstetrics and Gynecology, Oregon Health a Science University, Portland, OR, USA


11:00

AGNOSTIC IDENTIFICATION OF PLASMA BIOMARKERS FOR POSTPARTUM HEMORRHAGE RISK
Stephanie E. Reitsma1, Julia R. Barsoum2, Kirk C. Hansen3, Monika Dzieciatkowska3, Andra H. James4, Kjersti M. Aagaard5, Homa K. Ahmadzia2, Alisa S. Wolberg1. 1Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 2Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Science, Washington, DC, USA. 3Biochemistry and Molecular Genetics, The University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 4Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, and Department of Medicine under Hematology, Duke University School of Medicine, Durham, NC, USA. 5Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA


11:15

INDIVIDUAL PHARMACOKINETIC EVALUATION OF FIXED-SEQUENCE SINGLE-DOSE OCTOCOG ALFA, RURIOCTOCOG ALFA PEGOL, AND EFANESOCTOCOG ALFA IN ADULTS WITH SEVERE HEMOPHILIA A
Janice M. Staber1, Toshko Lissitchkov2, Anthony Chan3, Andrew Wilson4, Jennifer Dumont4, Annemieke Willemze 5. 1Division of Hematology/Oncology, Department of Pediatrics, Carver College of Medicine, University of Iowa Stead Family Children's Hospital, Iowa City, IA, USA. 2Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia, Bulgaria. 3McMaster Childrena, Hamilton, ON, Canada. 4Sanofi, Cambridge, MA, USA. 5Sanofi, Amsterdam, Netherlands


SHORT TALKS - INSIGHTS ON PLATELET BIOLOGY
Chicago Ballroom VII


10:30

DNA DAMAGE REPAIR INHIBITION: A CATALYST FOR ENHANCED MEGAKARYOPOIESIS AND THROMBOPOIESIS
Roelof H Bekendam1, 2, Andrew Stone1, Clementine Payne1, Virginia Camacho1, Isabelle Becker1, Estelle Carminita1, Maria Barrachina1, Kellie Machlus1, Joseph Italiano1. 1Vascular Biology Program, Boston Children's Hospital, Boston, MA, USA. 2Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA


10:45

INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA
Nichola Cooper1, A. J. Gerard Jansen2, Jiri Mayer3, Michael D Tarantino4, Remco Diab5, Brad Ward6, Ahmed Daak6, David J Kuter7. 1Hammersmith Hospital, London, United Kingdom. 2Erasmus MC, University Medical Center, Rotterdam, Netherlands. 3Masaryk University Hospital, Brno, Czech Republic. 4The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. 5Sanofi, Rotkreuz, LU, Switzerland. 6Sanofi, Cambridge, MA, USA. 7Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


11:00

NOVEL MECHANISM OF THROMBOSIS AND HEMOSTASIS INVOLVING PLATELET ALPHA-DYSTROGLYCAN
Viktor Prifti1, 2, Aron A. Shoara2, 3, Reid C. Gallant4, Sladjana Slavkovic2, 3, Kanwal Singh3, Margaret Rand1, Walter Kahr5, Yiming Wang2, Heyu Ni1, 2, 3. 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 2Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute, St. Michaela, Toronto, ON, Canada. 3Canadian Blood Services Centre for Innovation, Toronto, ON, Canada. 4Department of Medicine, University of Toronto, Toronto, ON, Canada. 5Department of Biochemistry, University of Toronto, Toronto, ON, Canada


11:15

UNC9426, A SELECTIVE TYRO3 INHIBITOR, DECREASES HUMAN PLATELET ACTIVATION AND INCREASES SURVIVAL IN A MURINE PULMONARY EMBOLISM MODEL
Samantha Judd1, Stephanie Springborn1, Adam Kidwell1, Deborah DeRyckere2, Douglas K. Graham2, Xiaodong Wang3, Brian Branchford1. 1Versiti Blood Research Institute, Wauwatosa, WI, USA. 2Aflac Cancer and Blood Disorders Center and Children's Healthcare of Atlanta, Atlanta, GA, USA. 3Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA


SHORT TALKS - THROMBOSIS - SPECIAL POPULATIONS
Sheraton Ballroom IV-V


RECLASSIFICATION OF ANTIPHOSPHOLIPID ANTIBODY SYNDROME ACCORDING TO THE 2023 ACR/EULAR GUIDANCE IN A PHARMACIST DIRECTED ANTICOAGULATION CLINIC
Catherine DeFazio1, Lara Horvath1, Jennifer Morgan1, Meaghan Murphy1, Ashley Shtoyko1, Elizabeth Phillips2. 1SUNY Upstate Medical University, Syracuse, NY, USA. 2St. John Fisher University, Wegmans School of Pharmacy, Rochester, NY, USA


UNDERSTANDING PRIMARY ANTIPHOSPHOLIPID SYNDROME: CORRELATING ANTIPHOSPHOLIPID ANTIBODIES PROFILE AND TITERS WITH THROMBOTIC AND HEMATOLOGICAL ACTIVITY
Amaya Llorente-ChAivez, Rodrigo Figueroa-MAcndez, Gabriela A. HernAindez-Molina, Alfonso Orozco-Collazo . Instituto Nacional de Ciencias MAcdicas y NutriciA³n Salvador ZubirAin, Mexico City, Mexico


NATIONALLY REPRESENTATIVE DATA ON CO-DIAGNOSIS, MORTALITY AND HEALTHCARE BURDEN OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED COVID-19 PATIENTS: RESULTS FROM THE NATIONAL INPATIENT SAMPLE
Giuseppe Maiocco1, Krish Khurana2, Nareg H. Roubinian3, Stephanie Bitner1, Waqas Azhar1, Hareena Sangha4, Nikhil Gupta5, Evan M. Bloch6, Michael B. Streiff6, Aaron A. R. Tobian6, Ruchika Goel1, 6, 7. 1Southern Illinois University School of Medicine, Springfield, IL, USA. 2SIU School of Medicine P4P program, Springfield, IL, USA. 3Vitalant Research Institute, San Francisco, CA, USA. 4University of Texas Southwestern School of Medicine, Dallas, TX, USA. 5Case Western Reserve University School of Medicine, Cleveland, OH, USA. 6Johns Hopkins University School of Medicine, Baltimore, MD, USA. 7Vitalant Corporate Medical Affairs, Scottsdale, AZ, USA


HEALTH LITERACY IN PEDIATRIC THROMBOSIS PATIENTS AND PARENTS/CAREGIVERS
Athena Mancini, Denise Bastas, Sindi Mukaj, Gina Wong, Leonardo R. BrandApo, Jennifer Vincelli , Diandra Rollan, M. Laura Avila. The Hospital for Sick Children, Toronto, ON, Canada

11:45 - 1:00 PM
PLENARY SESSION
SHARED DECISION MAKING BETWEEN PATIENTS AND CLINICIANS
Chair/Organizer: Leslie Lake
Sheraton Ballroom I-II


11:45

HOW CAN CLINICIANS HELP PATIENTS MAKE DECISIONS THAT ALIGN WITH THEIR VALUES?
Nadine Shehata.


12:10

SHARED DECISION MAKING WHEN THERE ARE LIMITED DATA - HEMOPHILIA GENE THERAPY
Lindsey George.


12:35

PATIENT INVOLVEMENT IN GUIDELINES - THE EXPERIENCE WITH THE ASH PEDIATRIC VTE GUIDELINE
Sara Vesely.